Skip to main content

MQX-503 FDA Approval Status

FDA Approved: No
Brand name: MQX-503
Dosage form: Topical Formulation
Company: MediQuest Therapeutics Inc
Treatment for: Raynaud's Disease

MQX-503 is a locally acting, topical formulation that is designed to be applied to prevent or treat the symptoms associated with Raynaud's Disease.

Development timeline for MQX-503

Apr 29, 2008MediQuest Therapeutics Submits New Drug Application to FDA for MQX-503 to treat Raynaud's Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.